Scientific Sessions 2024  /  The Future of Lipid Management: Using Lessons From Our Past  /  How Low and How Fast Should We Go with LDL-Cholesterol?
Logo

American Heart Association

  121
  0

Final ID:

How Low and How Fast Should We Go with LDL-Cholesterol?

  • Ray, Kausik  ( IMPERIAL COLLEGE LONDON , London , United Kingdom )
  • Lloyd-jones, Donald  ( Northwestern University , Chicago , Illinois , United States )
  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
    • Author Disclosures:
    Kausik Ray: DO have relevant financial relationships ; Research Funding (PI or named investigator):sanofi, daiichi sankyo, ultragenix, amarin:Active (exists now) ; Individual Stocks/Stock Options:New Amsteram Pharma, Scribe, Pemi31:Active (exists now) ; Speaker:Novartis, Daiichi, Merck, AZ, Novo Nordisk, BI, Sanofi, Amgen,:Active (exists now) ; Consultant:Kowa, Bayer,:Past (completed) ; Consultant:novartis, daiichi sankyo, AZ, MSD, Esoerion, Scribe, Silence Therapeutics, Cleerly, Nodthera, New Amsterdam Pharma, Amgen, Sanofi, Novo Nordisk, AZ,:Active (exists now) ; Research Funding (PI or named investigator):amgen:Past (completed) | Donald Lloyd-Jones: DO NOT have relevant financial relationships | Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
The Discovery of the LDL-Receptor and It's Potential as a Target

Goldstein Joseph, Brown Michael, Ballantyne Christie

The Evolution from Statins to Monoclonal Antibodies and Antisense Technology for Lipid Lowering

Michos Erin, Crooke Rosanne, Shapiro Michael

More abstracts from these authors:
New and Emerging Targets for Lowering LDL-Cholesterol and Triglycerides: ANGPTL3, CETP, APOC-III

Kastelein John, Ray Kausik

Meet the Trialist: ZODIAC: Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome

Ray Kausik

You have to be authorized to contact abstract author. Please, Login
Not Available